Introduction to Growth Factors
Growth factors are naturally occurring proteins and polypeptides capable of stimulating cellular growth, proliferation, healing, and cellular differentiation. They act as signaling molecules between cells, functioning through autocrine, paracrine, and endocrine mechanisms. In the context of autocrine signaling, growth factors are particularly significant because they allow cells to regulate their own behavior in a self-reinforcing manner.
The discovery of growth factors began with Stanley Cohen's identification of Nerve Growth Factor (NGF) and Epidermal Growth Factor (EGF) in the 1950s and 1960s, work that earned him the Nobel Prize in Physiology or Medicine in 1986. Since then, dozens of growth factor families have been identified, each with specific receptors, downstream signaling cascades, and biological functions. Understanding these molecules and their receptors is essential for comprehending autocrine signaling and its role in development, homeostasis, and disease.
The EGF Family: EGFR/ErbB Signaling
Ligands and Receptors
The Epidermal Growth Factor (EGF) family includes 11 ligands in mammals: EGF, TGF-α, amphiregulin (AREG), betacellulin (BTC), heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EREG), epigen (EPGN), and four neuregulins (NRG1-4). These ligands signal through four ErbB receptors: EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/HER4. The combinatorial diversity of ligand-receptor interactions creates a complex signaling network with context-dependent outputs.
ErbB2 is unique in that it has no known soluble ligand but serves as the preferred dimerization partner for all other ErbB receptors. ErbB3 lacks intrinsic kinase activity but can signal when heterodimerized with other ErbB members, particularly ErbB2. The ErbB2-ErbB3 heterodimer is one of the most potent signaling complexes and is a key driver of HER2-positive breast cancer.
Autocrine Significance
Autocrine EGF family signaling is prevalent in many cancers. Glioblastoma cells frequently express EGF and TGF-α alongside amplified EGFR. Head and neck squamous cell carcinomas overexpress amphiregulin in an autocrine fashion. In non-small cell lung cancer, mutations in EGFR create ligand-independent constitutive signaling, effectively mimicking a permanent autocrine activation state.
The PDGF Family
The Platelet-Derived Growth Factor family consists of four gene products that form five biologically active isoforms through homo- and heterodimerization: PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD. These ligands signal through two receptor tyrosine kinases, PDGFRα and PDGFRβ, which can also form homo- and heterodimers upon ligand binding.
PDGF was originally identified as a constituent of platelet granules that stimulated the growth of smooth muscle cells and fibroblasts. In autocrine signaling, PDGF plays critical roles in development (oligodendrocyte precursor cells produce PDGF-A and express PDGFRα) and disease (glioblastomas and dermatofibrosarcoma protuberans both exhibit PDGF autocrine loops). The drug imatinib, originally developed for BCR-ABL in chronic myeloid leukemia, also inhibits PDGFR and is effective in PDGF-driven tumors.
The FGF Family
The Fibroblast Growth Factor family is one of the largest, comprising 22 members (FGF1-FGF23; FGF15 is the mouse ortholog of FGF19) that signal through four FGF receptors (FGFR1-4). FGFs require heparan sulfate proteoglycans (HSPGs) as co-receptors for efficient receptor binding and activation, adding another layer of regulation to FGF signaling. Most FGFs function in autocrine or paracrine modes, while a subset (FGF15/19, FGF21, FGF23) functions as endocrine hormones.
FGF autocrine signaling is essential in embryonic development, particularly in limb bud formation and brain development. In cancer, FGFR amplification and mutations have been identified in breast cancer (FGFR1 amplification), bladder cancer (FGFR3 mutations), and cholangiocarcinoma (FGFR2 fusions), leading to the development of targeted therapies like erdafitinib, pemigatinib, and futibatinib.
The VEGF Family and Angiogenesis
Vascular Endothelial Growth Factors (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placental Growth Factor) are the primary drivers of blood vessel formation. They signal through VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3, along with neuropilin co-receptors. VEGF-A/VEGFR-2 signaling is the principal pathway regulating angiogenesis.
While VEGF signaling in endothelial cells is primarily paracrine (tumor cells secrete VEGF that acts on nearby blood vessel endothelial cells), many tumor cells also express VEGFRs and respond to their own VEGF production in an autocrine manner. This autocrine VEGF signaling promotes tumor cell survival, stemness, and resistance to cytotoxic therapy, independent of any angiogenic effect.
The Insulin/IGF Family
The insulin-like growth factor (IGF) system includes two ligands (IGF-1 and IGF-2), two receptors (IGF-1R and IGF-2R), and six binding proteins (IGFBP1-6) that modulate ligand bioavailability. IGF-1R is a receptor tyrosine kinase that activates both the MAPK/ERK and PI3K/Akt pathways. Autocrine IGF signaling has been implicated in breast cancer, prostate cancer, and sarcomas, where tumor cells produce IGF-1 or IGF-2 and express IGF-1R.
Clinical Applications and Therapeutic Targeting
The understanding of growth factor biology has led to a revolution in cancer therapy. Drugs targeting growth factor receptors include monoclonal antibodies (trastuzumab for HER2, bevacizumab for VEGF, cetuximab for EGFR), small-molecule kinase inhibitors (erlotinib for EGFR, imatinib for PDGFR, erdafitinib for FGFR), and antibody-drug conjugates (trastuzumab emtansine for HER2). Each of these therapeutic strategies fundamentally works by interrupting the autocrine or paracrine growth factor signaling that sustains tumor growth.